All News
BE MOBILE 1 Study - Bimekizumab in Non-Radiographic Axial Spondyloarthritis
Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
Read Article
Does T2T Lead to Fewer Gout Flares?
Lancet Rheumatology reports that a treat-to-target (T2T) goal of average serum urate less than 6 mg/dL is associated with an absence of gout flares and a reduction in the number of flares in the next 12 months.
Read Article
Fracture Risk with Osteoporosis Drug Holidays
While bisphosphonate drug holidays are recommended, there are few comparative studies.
Read Article
FDA has approved 2 JAK inhibitors for use in severe atopic dermatitis (eczema) - Abbvies upadacitinib (Rinvoq) and Pfizers abrocitinib (Cibinqo). https://t.co/WpCehmB7Vz https://t.co/qKoqV08Z86
Dr. John Cush RheumNow ( View Tweet)
J Rheum reports rheums may not be adequately screening for HBV, HCV when using tofacitinib & tocilizumab, despite rec's from CDC, AASLD, PI (but not ACR) to do so. TCZ & TOFA had partial screening (45% & 50%) or no screening (26% & 26%) https://t.co/y28kSJ1JgA
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus metanalysis of 41 studies, 17,270 pts shows that REMISSION was maintaned for 1 year in 42–88% of pts, and 5 yrs in 21–70%. Remission assoc w/ older age @dx, lower Dz activity, NO major organ involve. REM had less damage, better QOL https://t.co/1zPcITcYMo
Links:
Dr. John Cush RheumNow ( View Tweet)
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients
 https://t.co/dzDuza09JW https://t.co/HqL7nWdaP0
Links:
Dr. John Cush RheumNow ( View Tweet)
Register for RheumNow Live, March 19-20, 2022.
You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office.
You can also receive CME credit!
https://t.co/c7oLLCllM8 https://t.co/EGCGFilnVv
Links:
Dr. John Cush RheumNow ( View Tweet)
World Health Organization has recommended baricitinib & sotrovimab for COVID-19 (both already given EUA by the FDA). BARI (+/- steroids) given as 4 mg qd to severe hospitalized COVID. Sotrovimab, is for outpt, less severe disease. https://t.co/Hv8YdWUoYk https://t.co/l98zcyfGRk https://t.co/RAHKhqPWjp
Dr. John Cush RheumNow ( View Tweet)
JAMA reports that between Dec 2020 and July 2021, COVID-19 vaccination saved nearly 241,000 lives, prevented 1, 133, 617 hospitalizations and prevented more than 14 million COVID-19 cases (all in 1st 6 mos of the COVID vaccines) https://t.co/VIcwcPwbjn
Links:
Dr. John Cush RheumNow ( View Tweet)
Infliximab treatment of RMD/IMIDs by targeting drug levels (therapeutic drug monitoring) was superior to usual care in study with more sustained Dz control without worsening in 458 IMID pts Rx for 52 weeks (TDM 74% vs 70% standard Rx) https://t.co/Ef4b1fYwkw
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Why Are Physicians Silent About Outrageous Drug Prices?
https://t.co/VMEMLod8EP https://t.co/O6l5eLfFxo
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast! Dr. Cush reviews the news and journal articles from the past week on RheumNow. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogrens.
https://t.co/A2Kw7rtei6 https://t.co/U6tdmUkP73 https://t.co/Opo5cYc8UB
Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/72P5EHwD8l
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.
https://t.co/o2b1kwZ9QG https://t.co/ayaDlpl7DI
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/lY1MVpBoF1
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Duloxetine added to usual analgesics failed to improve pain in 132 hip or knee OA pts by WOMAC pain scores: 1) Dulox + usual care vs 2) Usual care showed no diff in pain at 3 mos or 12 mos. https://t.co/2luWWDYP81 https://t.co/KAmqlnofVv
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast! Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogrens.
https://t.co/Pg4snhCZyo https://t.co/ruzRs0ypcn https://t.co/zwI8baPEcn
Dr. John Cush RheumNow ( View Tweet)
Why Are Physicians Silent About Outrageous Drug Prices?
https://t.co/hLrUFCiKwm https://t.co/ZgRoW9Duo6
Links:
Dr. John Cush RheumNow ( View Tweet)
Hold Myophenolate or Not with COVID-19 Vaccination?
https://t.co/9Bp8huqJ6M https://t.co/AD11BmoZE8
Links:
Dr. John Cush RheumNow ( View Tweet)